This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies

This study has been terminated.
Information provided by:
Titan Pharmaceuticals Identifier:
First received: December 17, 2002
Last updated: January 21, 2011
Last verified: November 2006
This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment. This dosing cycle will be repeated. Adverse effects will be assessed and the levels of gallium in serum will be measured. Any effect of the drug on the cancer and any improvement in cancer-related symptoms will also be measured.

Condition Intervention Phase
Prostatic Neoplasms Multiple Myeloma Bladder Neoplasms Lymphoma Drug: Gallium maltolate Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Serum Level-targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Patients With Various Refractory Malignancies

Resource links provided by NLM:

Further study details as provided by Titan Pharmaceuticals:

Study Start Date: June 2001
Study Completion Date: March 2005
Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)
Detailed Description:
Gallium maltolate is an orally bioavailable form of gallium. This is a safety, pharmacokinetic and preliminary efficacy study. The primary objective of the study is to assess the safety profile in patients after oral administration of different doses of gallium maltolate for up to six 42-day cycles (28 days of gallium maltolate, followed by 14 days off treatment). In addition, serum concentrations of gallium and associated pharmacokinetic variables will be measured. From this information, an optimal dose will be selected for assessment of anti-tumor efficacy. The study assesses the effects of oral administration of gallium maltolate on pain resulting from bony metastasis, on biochemical measures of bone turnover, and on disease progression and overall survival in patients with various refractory malignancies. Patients may receive up to 6 cycles of the investigational agent.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with hormone refractory prostate cancer, refractory multiple myeloma, refractory bladder cancer, or malignant lymphoma;
  • life expectancy of ≥6 months,
  • Zubrod Performance Status of ≤2,
  • adequate bone marrow function, renal function, liver function and pulmonary function;
  • age ≥ 18 years;
  • willing and able to give informed consent; and
  • effective contraceptive use or non child-bearing potential.

Exclusion Criteria:

  • 10% weight loss in the previous 3 months;
  • active serious infection not controlled by antibiotics;
  • initiation of bisphosphonates treatment within 30 days;
  • participation in other research study within 30 days;
  • uncontrolled brain metastasis,
  • prior intrathecal chemotherapy or whole-brain radiotherapy,
  • inability to comply with protocol or undergo specified tests;
  • other active malignancy;
  • optic neuritis, and
  • routine use of diuretics (for initial phase of study only).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00050687

United States, Arkansas
Highlands Oncology Group, PA
Springdale, Arkansas, United States, 72764
United States, California
California Cancer Care
Greenbrae, California, United States, 94904
Stanford University
Palo Alto, California, United States, 94303
United States, Michigan
Southfield Oncology Institute
Southfield, Michigan, United States, 48076
United States, New York
New York Presbyterian Hospital
New York, New York, United States, 10021
Sponsors and Collaborators
Titan Pharmaceuticals
  More Information Identifier: NCT00050687     History of Changes
Other Study ID Numbers: TTP-370-01-01
Study First Received: December 17, 2002
Last Updated: January 21, 2011

Additional relevant MeSH terms:
Multiple Myeloma
Prostatic Neoplasms
Urinary Bladder Neoplasms
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Urologic Neoplasms
Urinary Bladder Diseases
Urologic Diseases processed this record on August 17, 2017